Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00803374 | Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | Phase 1 | withdrawn | Dec 5, 2008 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00184288 | Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response. | — | withdrawn | Sep 16, 2005 | Norwegian University of Science and Technology | no patients recruited | Enrollment / accrual |
| NCT00060710 | CP-461 in the Treatment of Patients With Advanced Melanoma | Phase 2 | terminated | May 13, 2003 | Astellas Pharma Inc | not stated | Not stated |
| NCT00747825 | Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma | Phase 1 | terminated | Sep 5, 2008 | Molecular Insight Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00496223 | A Phase I/II Study of Sunitinib and Dacarbazine | Phase 1 / Phase 2 | terminated | Jul 4, 2007 | H. Lee Moffitt Cancer Center and Research Institute | toxicities required dose reduction compromising effectiveness and PI left Moffitt | Safety / toxicity |
| NCT00735332 | Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma | Phase 2 | terminated | Aug 14, 2008 | Thallion Pharmaceuticals | License termination. | Other (stated, no rule matched) |
| NCT00667901 | Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by… | Phase 1 | terminated | Apr 28, 2008 | University of Medicine and Dentistry of New Jersey | All enrollment, treatment, follow-up \& data analysis completed | Enrollment / accrual |
| NCT00963664 | Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma | Phase 2 | withdrawn | Aug 21, 2009 | NeoPlas Innovation | Modifications will be necessary before full IRB approval will be secured. | Other (stated, no rule matched) |
| NCT00675727 | Safety Study of CADI-05 in Patients With Advanced Stage Melanoma | Phase 1 / Phase 2 | terminated | May 12, 2008 | Cadila Pharnmaceuticals | DSMB reviewed data of 1st 10 subjects; determined no safety concerns. Efficacy as a single agent in… | Safety / toxicity |
| NCT00733798 | A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant… | Phase 1 / Phase 2 | terminated | Aug 13, 2008 | TransMolecular | For Strategic Reasons | Sponsor / business decision |
| NCT00272415 | A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety,… | Phase 1 | terminated | Jan 6, 2006 | Genentech, Inc. | not stated | Not stated |
| NCT00304200 | Temodar and Sutent as Therapy for Melanoma | Phase 1 / Phase 2 | terminated | Mar 17, 2006 | Northern California Melanoma Center | Funding was inadequate to continue; Companies requested closure. | Funding |
| NCT00160992 | Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed… | Phase 1 | suspended | Sep 12, 2005 | University of Lausanne Hospitals | not stated | Not stated |
| NCT00087477 | A Pilot Study of Pivanex in Patients With Malignant Melanoma | Phase 1 / Phase 2 | terminated | Jul 13, 2004 | Titan Pharmaceuticals | not stated | Not stated |
| NCT00042497 | Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma | Phase 2 | suspended | Aug 1, 2002 | Anosys | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 21, 2011source: clinicaltrials